Therapeutic Advances in Infectious Disease
Overview
Therapeutic Advances in Infectious Disease is a scientific journal, published by Sage Publications since 2013 in English. The journal's country of origin is United Kingdom and its primary focus area is infectious diseases.
Details
Details
Abbr.
Ther Adv Infect Dis
Publisher
Sage Publications
Start
2013
End
Continuing
Frequency
Bimonthly
p-ISSN
2049-9361
e-ISSN
2049-937X
Country
United Kingdom
Language
English
Specialty
Infectious Diseases
Metrics
Metrics
h-index / Ranks: 10631
29
SJR / Ranks: 3728
1015
CiteScore / Ranks: 5670
4.60
Recent Articles
1.
Corrigendum to "Serine protease inhibitors could be of benefit in the treatment of COVID-19 disease"
Ther Adv Infect Dis
. 2025 Mar;
12:20499361241294158.
PMID: 40041252
[This corrects the article DOI: 10.1177/20499361211032048.].
2.
Que A, Tran A, Trang T, Tran T, Bui N, Lai C
Ther Adv Infect Dis
. 2025 Mar;
12:20499361251315346.
PMID: 40027950
Background: Urinary tract infection (UTI) is one of the most common bacterial infections in clinical practice. Given the rapid increase in antimicrobial resistance and the scarcity of new antibiotics, along...
3.
Ther Adv Infect Dis
. 2025 Mar;
12:20499361251323437.
PMID: 40027949
[This corrects the article DOI: 10.1177/20499361241298857.].
4.
Pitua I, Bongomin F
Ther Adv Infect Dis
. 2025 Mar;
12:20499361251323709.
PMID: 40027948
Background: Mpox was declared a Public Health Emergency of International Concern by the World Health Organization in August 2024, following an outbreak in Africa. Public engagement on YouTube provides insights...
5.
Creasy S, Egan J, Krier S, Townsend J, Ward J, Hawk M, et al.
Ther Adv Infect Dis
. 2025 Feb;
12:20499361251323721.
PMID: 40017794
Background: In addition to structural interventions such as syringe services and naloxone distribution, harm reduction (HR) is also a approach to care encompassing principles such as patient autonomy and pragmatism...
6.
Dong C, Zhang R, Li S, Chen J, Liu Y, Xia X, et al.
Ther Adv Infect Dis
. 2025 Feb;
12:20499361241308641.
PMID: 40007941
Background: At present, there is a need for more substantial real-world evidence on the factors influencing the effectiveness of tuberculosis (TB) treatment in HIV/TB co-infected patients. Objectives: This retrospective study...
7.
Fuller C, Bagga R, Bado E, Ahmad S, Boggild A
Ther Adv Infect Dis
. 2025 Feb;
12:20499361251319659.
PMID: 39975687
Both acute traveler's diarrhea and sexually transmitted infections are common causes of fever in the returned traveler, with the male sex corresponding to two-fold increased odds of a sexually transmitted...
8.
Vasishta S, Aberg J, Patel G, Gownivaripally P, Rana M
Ther Adv Infect Dis
. 2025 Feb;
12:20499361251320711.
PMID: 39968165
Background: Immunocompromised adults may experience severe COVID-19 outcomes, necessitating a multifaceted treatment approach. Studies from the Delta period showed benefit from monoclonal antibody (mAb) therapy that was most pronounced among...
9.
Dakorah M, Aninagyei E, Attoh J, Adzakpah G, Tukwarlba I, Acheampong D
Ther Adv Infect Dis
. 2025 Feb;
12:20499361251319665.
PMID: 39968164
Background: The proliferation of parasites resistant to antimalarial drugs poses a serious threat to human life and remains an obstacle to managing and eradicating . The surveillance of molecular markers...
10.
Pitua I, Kirya M, Kiberu D, Nabaasa S, Namiiro A, Segawa M, et al.
Ther Adv Infect Dis
. 2025 Feb;
12:20499361251319655.
PMID: 39949512
Background: Tuberculosis (TB) remains a significant global health challenge, especially among people living with HIV. Drug-resistant TB (DR-TB) complicates treatment outcomes in high-burden countries like Uganda, particularly for adolescents and...